Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

efficacy in inflammatory bowel disease targets and look forward to future research to uncover the product's potential in this important therapeutic area."

About the Studies

Results from CLIN 1001-004 were presented at ACG in a poster entitled "Larazotide Acetate Prevents Immunologic Changes Induced by Gluten Challenge in Celiac Disease Patients" (Poster 446). The randomized, double-blind, placebo-controlled study was designed to evaluate the effects of larazotide acetate on the systemic immunologic changes induced by a two week gluten challenge in patients with celiac disease. Study results showed that larazotide acetate was well tolerated and showed signs of efficacy in preventing immunologic changes induced by gluten challenge in patients with celiac disease, consistent with the beneficial effects observed on intestinal permeability, signs and symptoms. Clinical findings included:

-- Gluten challenge in the placebo (control) group resulted in an increase in circulating regulatory T cells (CD4, CD25, FOX-P3+) and a decrease in B cells (CD3, CD19+). These changes were completely prevented in the group on larazotide acetate.

-- There was a small, not statistically significant increase in the anti-tTG titer in the placebo (control) group, which was prevented in the group on larazotide acetate.

-- Other trends in specific monocyte populations induced by gluten challenge were also prevented to varying extents by larazotide acetate.

The second presentation, "Larazotide Acetate, a Tight Junction Inhibitor Peptide, Inhibits Epithelial Permeability Induced by TNF-alpha and IL-4" (Poster 1052) included results from a study investigating the effect of larazotide acetate on tumor necrosis factor (TNF-alpha) and interleukin (IL-4) induced permeability. The study showed that larazotide acetate inhibited increased permeability mediated with TNF-alpha and IL-4, which suggests the potential of larazotide acetate as a therapeutic agent for
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Timothy E. Morris , chief financial officer  will ... the events are as follows: Mizuho Third ... Location:  The Omni Berkshire Place, New York ...
(Date:4/30/2015)... 2015 Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its first quarter ... for the first quarter of 2015 was $116.2 million, ... of 2014, and down $5.3 million or 4.4% from ... 2015 net income as reported in accordance with U.S. ...
(Date:4/30/2015)... JOLLA, Calif. , April 30, 2015   ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended March ... U.S. financial markets close. Regulus will ... 7, 2015, at 5:00 pm Eastern Daylight Time to ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... 27, 2011 Bend Research Inc. ( www.bendresearch.com ), a ... new president. Jim Nightingale, who has worked ... in the firm,s 36-year history. Nightingale will ... Bend Research Chief Executive Officer (CEO) and chairman of the ...
... July 27, 2011 Assured Pharmacy, Inc. (Other OTC: ... to more than 3,000 sufferers of chronic pain, announced ... Kansas for its fifth pharmacy location.  Subject to regulatory ... during the Fourth Quarter of 2011.  It will join ...
Cached Medicine Technology:Bend Research Inc. Names New President 2Assured Pharmacy Signs Lease in Kansas City, Kansas for its Fifth Pharmacy Location 2Assured Pharmacy Signs Lease in Kansas City, Kansas for its Fifth Pharmacy Location 3
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch as ... the latest and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... to make a difference. , In this material world, almost ... aren’t about money, which is why those things should be ...
(Date:5/2/2015)... 2015 It’s a pattern that won’t ... strikes anywhere on this planet, cyber scammers will immediately ... compassion for their own personal gain. And on ... Team) issued an alert titled “Nepal Earthquake Disaster ... citing the earthquake in Nepal. The scam emails may ...
(Date:5/2/2015)... 02, 2015 “ Peachtree Audio ” ... Tech Report, which features the latest and coolest technology ... and special reporter for NewsWatch, conducted the review and ... equipment. , Music is an important part of ... pampered and given the royal treatment. Peachtree Audio does ...
(Date:5/2/2015)... Chicago, IL (PRWEB) May 02, 2015 Kare ... to provide support for busy caregivers. Kare Visits offers ... hospitals, and assisted living facilities. According to the ... caregivers spend an average of 20 hours a week caring ... fraction of the cost to hire a nurse, a caregiver ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
Breaking Medicine News(10 mins):Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... ... to distributors, re-sellers, and customers. It was ultimately a lavish gift for an industry that ... ... a custom made bottle of a well known whiskey, designed especially for their company. The ...
... Spanish . , Higher rates of colorectal cancer ... by differences in health care utilization, and less by biology, ... National Cancer Institute (NCI), part of the National Institutes of ... people who were screened for colorectal cancer, researchers found that ...
... at initial screening often didn,t have recommended colonoscopy, study ... Americans are less likely than whites to have a ... sigmoidoscopy screening test, says a new study. , ... risk for colorectal cancer and more likely to die ...
... patients often receive better care than normal-weight peers, study ... concerns that obese Americans get second-rate health care, a ... of medical attention they receive versus that of normal-weight ... the obese may actually be higher and more aggressive ...
... support care between office visits, boost efficiency and convenience, ... the April Health Affairs suggests how to ... patients how they like it and what they want. ... health information technology they use is meeting their needs ...
... ... affording it an end to end marketing platform in China. , ... Oakland, CA (PRWEB) April 2, 2010 ... business process outsourcing company, Mag2U, to enhance DDKU’s growing internet presence as well as ...
Cached Medicine News:Health News:Sinrex Male Enhancement Manufacturer Gifts Custom Bottle of Whiskey to Customers 2Health News:New study implicates health care utilization, over biology, in colorectal cancer disparities 2Health News:New study implicates health care utilization, over biology, in colorectal cancer disparities 3Health News:New study implicates health care utilization, over biology, in colorectal cancer disparities 4Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Obese Americans Get High Quality Medical Care 2Health News:Obese Americans Get High Quality Medical Care 3Health News:Want better health information technology? Ask patients how they want it 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 3
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... The INFINITI 4F, 5F, ... diagnostic catheters is ideal ... products incorporate state-of-the-art technology ... to deliver better responsiveness, ...
Medicine Products: